Navigation Links
Dangerous experiment in fetal engineering
Date:8/3/2012

CHICAGO --- A new paper just published in the Journal of Bioethical Inquiry uses extensive Freedom of Information Act findings to detail an extremely troubling off-label medical intervention employed in the U.S. on pregnant women to intentionally engineer the development of their fetuses for sex normalization purposes.

The paper is authored by Alice Dreger, professor of clinical medical humanities and bioethics at Northwestern University Feinberg School of Medicine and is co-authored by Ellen Feder, associate professor of philosophy and religion at American University, and Anne Tamar-Mattis, executive director of Advocates for Informed Choice.

The pregnant women targeted are at risk for having a child born with the condition congenital adrenal hyperplasia (CAH), an endocrinological condition that can result in female fetuses being born with intersex or more male-typical genitals and brains. Women genetically identified as being at risk are given dexamethasone, a synthetic steroid, off-label starting as early as week five of the first trimester to try to "normalize" the development of those fetuses, which are female and CAH-affected. Because the drug must be administered before doctors can know if the fetus is female or CAH-affected, only one in eight of those exposed are the target type of fetus.

The off-label intervention does not prevent CAH; it aims only at sex normalization. Like Diethylstilbestrol (DES) -- which is now known to have caused major fertility problems and fatal cancers among those exposed in utero -- dexamethasone is a synthetic steroid. Dexamethasone is known -- and in this case intended -- to cross the placental barrier and change fetal development. Experts estimate the glucocorticoid dose reaching the fetus is 60 to 100 times what the body would normally experience.

The new report provides clear evidence that:

  • For more than 10 years, medical societies repeatedly but ultimately impotently expressed high alarm at use of this off-label intervention outside prospective clinical trials, because it is so high risk and because nearly 90 percent of those exposed cannot benefit.

  • Mothers offered the intervention have been told it "has been found safe for mother and child" but in fact there has never been any such scientific evidence.

  • The U.S. Food and Drug Administration has indicated it cannot stop advertising of this off-label use as "safe for mother and child" because the advertising is done by a clinician not affiliated with the drug maker.

  • A just-out report from Sweden in the Journal of Clinical Endocrinology and Metabolism documents a nearly 20 percent "serious adverse event" rate among the children exposed in utero.

  • Clinician proponents of the intervention have been interested in whether the intervention can reduce rates of tomboyism, lesbianism and bisexuality, characteristics they have termed "behavioral masculinization."

  • The National Institutes of Health has funded research to see if these attempts to prevent "behavioral masculinization" with prenatal dexamethasone are "successful."

  • The United States' systems designed to prevent another tragedy like DES and thalidomide -- involving de facto experimentation on pregnant women and their fetuses -- appear to be broken and ineffectual.


'/>"/>
Contact: Marla Paul
Marla-Paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related medicine news :

1. Dangerous caregivers for elderly
2. Dangerous Rage May Be Common Among U.S. Teens
3. New iTeen365 White Paper Identifies Dangerous Driving Distractions – Offers Solutions for Parents of Teen Drivers
4. U.S. Blood Supply at Dangerously Low Levels: Red Cross
5. Blood test for pregnant women could predict risk of having dangerously small babies
6. Prenatal exposure to pollution especially dangerous for children with asthma
7. Young Risk-Takers Drawn to Dangerous Choking Game
8. Experimental Drug Suppresses Appetite in Mice: Study
9. Experimental Chemical Helps Blind Mice See
10. Experimental drug may extend therapeutic window for stroke
11. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Portland, Oregon (PRWEB) , ... January 23, 2017 ... ... systems, announced today it has earned organic certification under the USDA National Organic ... the USDA Organic Certification process, we have established organic production and handling systems ...
(Date:1/23/2017)... ... ... “The Inn at the Mill”: a story of love and redemption, hope and uncertainty ... and content. , “The Inn at the Mill” is the creation of published author, ... and is now living in Berks County on Crow Hill. The inn, the ...
(Date:1/23/2017)... Georgia (PRWEB) , ... January 23, 2017 , ... Valentine’s Day is a time when ... their loved ones. For those who may be looking for the ideal present, Atlanta-based ... certificate and get an additional $25 free. Or, spend $200 and get $50 free. ...
(Date:1/21/2017)... FL (PRWEB) , ... January 21, 2017 , ... Caronlab ... recently attended the January ECRM Trade Show in Hilton Head, SC, where it benefited ... reputation for the quality of its beauty and wellness products. At this trade show, ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting ... family, friends, and community. “Coming Home 2017” will be held on Friday ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23. Januar 2017  ResMed (NYSE: RMD ... 3B Medical ( Winter Haven, Florida ) ... über die Beilegung aller globalen Rechtsstreitigkeiten zwischen den Parteien ... ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren an ... 3B leisten, um das in Florida ...
(Date:1/23/2017)... Jan. 23, 2017 Just two weeks remain until legal experts ... gather in Central London to discuss the flow ... in the market, Parallel Trade 2017 . In the ... of attendees which is available to read in the event download ... Some of ...
(Date:1/21/2017)... According to a new market research report "Life Science ... Component (Software, Service), Delivery (On premise, Cloud), End user (Pharmaceutical, Biotechnology, ... market is expected to reach USD 24.73 Billion by 2021 from ... the forecast period. Continue Reading ... ...
Breaking Medicine Technology: